Review of the evidence base of representatives of the group of sodium-glucose co-transporter 2 inhibitors available at the Ukrainian market (literature review)

Abstract

The article presents an analysis of the results of randomized clinical studies of glucose lowering drugs from the class of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes: EMPA-REG OUTCOME® with empagliflozin and DECLARE-TIMI 58® with dapagliflozin. It is shown how the results of these trials have influenced the formation of the latest algorithms for antihyperglycemic therapy of patients with type 2 diabetes.

Keywords

• empagliflozin
• dapagliflozin
• sodium-glucose transport protein 2 inhibitors
• type 2 diabetes
• review